文献速递心力衰竭与心肌病

遗传性肥厚型心肌病外显率荟萃分析与向疾病转化系统综述

Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2023-11-06

该系统综述与荟萃分析评估了肌节或肌节相关基因致病/可能致病变异(P/LP)在肥厚型心肌病(HCM)中的外显率。家族/临床研究中,级联筛查发现携带P/LP变异的非先证者亲属外显率为57%(95%CI 52%-63%),平均诊断年龄38岁;而偶然发现的P/LP变异携带者外显率仅约11%。纵向家族研究中,平均随访约8年表型转化率为15%。

要点

  • 家族级联筛查中P/LP变异携带者外显率57%,平均诊断年龄38岁。
  • 偶然发现的P/LP变异携带者外显率约11%,显著低于家族研究。
  • 纵向家族研究平均随访约8年,表型转化率为15%。

核心结论

  • P/LP变异的外显率高度可变,受尚未明确的遗传和环境因素影响。
  • 家族级联筛查中非先证者亲属外显率为57%(95%CI 52%-63%),平均诊断年龄38岁(95%CI 36%-40%)。
  • 偶然发现的P/LP变异携带者外显率约11%,范围从0%(ARIC)到18%(UK Biobank)。
  • 纵向家族研究汇总表型转化率为15%,平均随访约8年,起始平均年龄约16岁。

研究设计与样本

  • 系统文献检索共评估455篇全文手稿和文章。
  • 采用随机效应广义线性混合模型荟萃分析,对比临床研究与人群/社区研究中肌节相关基因的横断面患病率与外显率。
  • 额外分析纵向家族/临床研究,调查随访期间从亚临床向显性HCM的表型转化率。

主要发现

  • 家族/临床研究中,确诊HCM患者肌节变异患病率为34%。
  • 外显率因基因而异:MYL3约32%,MYBPC3约55%,TNNT2和TNNI3约60%,MYH7约65%。
  • 人群遗传学研究中P/LP肌节变异背景患病率<1%。
  • 短期基因特异性表型转化率:MYBPC3约12%,MYH7约23%。

关键数值与推荐

  • 家族级联筛查中P/LP变异携带者外显率57%(95%CI 52%-63%)。
  • 偶然发现的P/LP变异携带者外显率约11%,范围0%(ARIC)至18%(UK Biobank)。
  • 纵向家族研究汇总表型转化率15%,平均随访约8年,起始平均年龄约16岁。
  • 基因特异性外显率:MYL3约32%,MYBPC3约55%,TNNT2和TNNI3约60%,MYH7约65%。

临床怎么用

  • 家族级联筛查中P/LP变异携带者外显率较高,应进行定期临床评估和随访。
  • 偶然发现的P/LP变异携带者外显率较低,咨询时应考虑基因和情境差异。
  • 基因特异性外显率数据可用于个体化风险分层和随访策略制定。

局限性

  • 外显率受尚未明确的遗传和环境因素影响,难以可靠预测。
  • 需要更多纵向研究以了解家族和社区中真实终生外显率及亚临床向显性HCM转化的驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease because penetrance (proportion of sarcomere or sarcomere-related P/LP variant carriers who develop disease) is variable, age dependent, and not reliably predicted. METHODS: A systematic search of the literature was performed. We used random-effects generalized linear mixed model meta-analyses to contrast the cross-sectional prevalence and penetrance of sarcomere or sarcomere-related genes in 2 different contexts: clinically-based studies on patients and families with HCM versus population or community-based studies. Longitudinal family/clinical studies were additionally analyzed to investigate the rate of phenotypic conversion from subclinical to overt HCM during follow-up. RESULTS: In total, 455 full-text manuscripts and articles were assessed. In family/clinical studies, the prevalence of sarcomere variants in patients diagnosed with HCM was 34%. The penetrance across all genes in nonproband relatives carrying P/LP variants identified during cascade screening was 57% (95% CI, 52%-63%), and the mean age at HCM diagnosis was 38 years (95% CI, 36%-40%). Penetrance varied from ≈32% for MYL3 (myosin light chain 3) to ≈55% for MYBPC3 (myosin-binding protein C3), ≈60% for TNNT2 (troponin T2) and TNNI3 (troponin I3), and ≈65% for MYH7 (myosin heavy chain 7). Population-based genetic studies demonstrate that P/LP sarcomere variants are present in the background population but at a low prevalence of <1%. The penetrance of HCM in incidentally identified P/LP variant carriers was also substantially lower at ≈11%, ranging from 0% in Atherosclerosis Risk in Communities to 18% in UK Biobank. In longitudinal family studies, the pooled phenotypic conversion across all genes was 15% over an average of ≈8 years of follow-up, starting from a mean of ≈16 years of age. However, short-term gene-specific phenotypic conversion varied between ≈12% for MYBPC3 and ≈23% for MYH7. CONCLUSIONS: The penetrance of P/LP variants is highly variable and influenced by currently undefined and context-dependent genetic and environmental factors. Additional longitudinal studies are needed to improve our understanding of true lifetime penetrance in families and in the community and to identify drivers of the transition from subclinical to overt HCM.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Topriceanu CC, Pereira AC, Moon JC, et al. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation. 2023. PMID: 37929589. doi:10.1161/CIRCULATIONAHA.123.065987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。